After steering made-in-China CAR-T all the way from obscurity to approval, Frank Fan resigns from Legend
Now that Legend Biotech has secured its first approval for the J&J-partnered BCMA CAR-T, it’s saying goodbye to its founder and CSO.
Frank Fan — who began working on the cell therapy in 2014 when it was still housed in the Chinese CRO GenScript, took it to the international spotlight at 2017’s ASCO conference with stunning data, negotiated a deal with J&J’s Janssen for it with $350 million upfront and steered it to an FDA OK days ago — resigned from the company effective March 30, the company revealed Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.